Malignant neoplasm of uterine adnexa, unspecified
ICD-10 C57.4 is a billable code used to indicate a diagnosis of malignant neoplasm of uterine adnexa, unspecified.
C57.4 refers to malignant neoplasms located in the uterine adnexa, which includes the ovaries, fallopian tubes, and surrounding connective tissues. These tumors can arise from various cell types and may present with a range of symptoms, including abdominal pain, abnormal bleeding, and changes in menstrual cycles. Diagnosis typically involves imaging studies such as ultrasound or CT scans, and may be confirmed through biopsy. The staging of these malignancies is crucial for determining treatment options and prognosis, often utilizing the FIGO (International Federation of Gynecology and Obstetrics) staging system. CA-125, a tumor marker, is frequently used in the monitoring and management of ovarian cancer, although it is not specific to malignancy and can be elevated in benign conditions. Treatment approaches may include surgical intervention, chemotherapy, and radiation therapy, depending on the stage and type of cancer. Accurate coding is essential for appropriate reimbursement and tracking of cancer incidence and outcomes.
Detailed pathology reports, imaging studies, and treatment plans must be documented.
Patients presenting with pelvic masses, abnormal CA-125 levels, or abnormal imaging findings.
Ensure accurate staging and documentation of any concurrent conditions to avoid coding errors.
Clear imaging reports indicating findings related to the adnexa and any recommendations for further evaluation.
Imaging studies performed for suspected adnexal masses or follow-up of known malignancies.
Radiologists should provide detailed descriptions of findings to support accurate coding.
Used when surgical intervention is performed for malignant neoplasm of the uterine adnexa.
Operative reports detailing the procedure and findings.
Gynecologic oncologists should ensure all findings are documented to support coding.
CA-125 is a tumor marker often used in the diagnosis and monitoring of ovarian cancer. While it is not specific to malignancy, elevated levels can support the diagnosis of malignant neoplasms of the uterine adnexa when documented appropriately.
